Existing investors provide funding to finish international RESPONDER-HF trial
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced the successful closure of a $55 million funding round from the company’s existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two strategic investors.
Health Technology Insights: J&J’s Dual CAR-T Shows Promise in Large B-cell Lymphoma
The funds will be used to complete the ongoing RESPONDER-HF trial, a double-blinded, randomized, sham-controlled, confirmatory trial of the Corvia Atrial Shunt currently underway at more than 65 institutions on three continents. The study is expected to generate the final supportive clinical data required for FDA approval of the shunt as a breakthrough treatment for heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).
Health Technology Insights: Prodigy Weight Loss Charges onto the National Stage with Celly Health Partnership
“We are profoundly grateful for the unwavering support of our longstanding investors as we advance toward FDA submission of the Corvia Atrial Shunt,” said George Fazio, CEO of Corvia Medical. “Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide.”
Paul LaViolette, Board Chair of Corvia Medical, added, “We firmly believe Corvia has the potential to fundamentally alter the landscape of heart failure treatment, and our investors share that vision. With these resources, we are well-equipped to drive the company through the approval process and introduce this groundbreaking therapy to the market.”
Health Technology Insights: Skypoint Launches AI Tools to Boost Clinical Workflow and SDOH
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
